Results 41 to 50 of about 1,481 (180)

Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study

BMC Psychiatry, 2021
Background Esketamine nasal spray (Spravato) in conjunction with oral antidepressants (ADs) is approved in the European Union, United States, and other markets for treatment-resistant depression (TRD).
Nagahide Takahashi, Aya Yamada, Ayako Shiraishi, Hiroko Shimizu, Ryosuke Goto, Yushin Tominaga   +5 more
doaj   +1 more source

Esketamine in patient with treatment resistant depression: Outcome of the temporary authorization for use programme in France

European Psychiatry, 2021
Introduction Esketamine nasal spray has been developed for patients with treatment resistant depression. Objectives A cohort Temporary Authorization for Use (ATUc) allowed to collect for a 6-month period the first data in real life Methods On 02/08/
E. Gaudre Wattinne, L. Mekaoui, M. Rothärmel, M.A. Codet, S. Bouju   +4 more
doaj   +1 more source

Montgomery‐Åsberg Depression Rating Scale factors in treatment‐resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine

International Journal of Methods in Psychiatric Research, 2022
Objective Derive and confirm factor structure of the Montgomery‐Åsberg Depression Rating Scale (MADRS) in patients with treatment‐resistant depression (TRD) and evaluate how the factors evident at baseline change over 4 weeks of esketamine treatment ...
Stephane Borentain, Jagadish Gogate, David Williamson, Thomas Carmody, Madhukar Trivedi, Carol Jamieson, Patricia Cabrera, Vanina Popova, Ewa Wajs, Allitia DiBernardo, Ella J. Daly   +10 more
doaj   +1 more source

Safety of esketamine nasal spray: Analysis of post-marketing reports submitted to the FDA adverse event reporting system in the first year on the market

European Psychiatry, 2021
Introduction The approval of the esketamine nasal spray for treatment-resistant depression in March 2019 by the Food and Drug Administration (FDA), and few months later by the European Medicine Agency, triggered a vivid debate and many concerns, mainly
C. Gastaldon, E. Raschi, J. Kane, C. Barbui   +3 more
doaj   +1 more source

Nowe leki w psychiatrii – kariprazyna, lurazydon, esketamina [PDF]

, 2021
Introduction: Invariably, the search for an “ideal drug” in psychiatry has been going for years, one that is safe and effective, prevents relapse and shows the least possible side effects.
Masiak, Jolanta, Masiak, Jolanta, Pożarowska, Kinga, Pożarowska, Kinga, Rudziński, Gracjan, Rudziński, Gracjan, Rusinek, Adam, Rusinek, Adam, Soroka, Ewelina, Soroka, Ewelina   +9 more
core   +2 more sources

Gender differences in response and remission rates among patients receiving esketamine

European Psychiatry, 2023
Introduction Depressive disorders are among the leading causes of disability. The lifetime risk for developing clinically significant depression is estimated around 15%.
A. T. Guterman, K. Feffer, A. Z. Gershi
doaj   +1 more source

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients with Treatment-Resistant Depression: A Randomized Clinical Trial [PDF]

, 2019
Importance: Controlled studies have shown short-term efficacy of esketamine for treatment-resistant depression (TRD), but long-term effects remain to be established.
Bitter, I., Blier, P., Cubala, W. J., Daly, E. J., Divacka, I., Drevets, W. C., Duca, A. R., Fagiolini, A., Hough, D., Janik, A., Lane, R., Li, H., Li, X., Lim, P., Manji, H., Molero, P., Shelton, R. C., Singh, J. B., Thase, M. E., Trivedi, M. H., Winokur, A., Zajecka, J., Zhang, Y.   +22 more
core   +1 more source

Are we repeating mistakes of the past? A review of the evidence for esketamine – CORRIGENDUM [PDF]

, 2021
It should be emphasised that Table 1 in the Analysis1 combines data from Phase 2 trials (including open-label and placebo-controlled trial periods) and Phase 3 trials (placebo-controlled efficacy studies, a maintenance of effect study and a long-term ...
Horowitz, Mark A, Moncrieff, Joanna
core  

Therapeutic environment for esketamine a policy [PDF]

, 2023
This project aimed to develop a structured policy surrounding the therapeutic environment of esketamine to provide continuity of care and maximize therapeutic benefits while mitigating possible side effects of esketamine. A literature review for the most
Stewart, Sierra
core   +1 more source

Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression [PDF]

Journal of Comparative Effectiveness Research, 2021
Aim: Estimate the cost-per-remitter with esketamine nasal spray plus an oral antidepressant (ESK + oral AD) versus oral AD plus nasal placebo (oral AD + PBO) among patients with treatment-resistant depression. Patients & methods: An Excel-based model was developed to estimate the cost-per-remitter ...
Urvi Desai, Noam Y Kirson, Andrea Guglielmo, Hoa H Le, Timothy Spittle, Joshua Tseng-Tham, May Shawi, John J Sheehan   +7 more
openaire   +2 more sources